Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

Abstract: Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Abstract: A trackpad includes: a substrate; a circuit board coupled to the substrate for detecting a position of an object adjacent the substrate, the circuit board including a first plate; a second plate including a spring element, wherein a spacer couples the circuit board and the spring element to each other, the spring element facilitating first movement of the substrate and the circuit board relative to the second plate; and a capacitive force sensor that detects a capacitance of the first plate and the second plate. A trackpad can include a spacer coupling the circuit board and the spring element to each other, and facilitating second movement of at least the substrate and the circuit board by a haptic feedback component.

Abstract: A trackpad includes: a substrate; a circuit board coupled to the substrate for detecting a position of an object adjacent the substrate; a haptic feedback component coupled to the circuit board; a first plate coupled to the circuit board; a second plate including a spring element, a spacer coupling the circuit board and the spring element to each other, the spring element facilitating first movement of the substrate, the circuit board and the first plate relative to the second plate, the spacer facilitating second movement of at least the substrate and the circuit board by the haptic feedback component; and a capacitive force sensor that detects a capacitance of the first plate and the second plate. A trackpad can include a circuit board coupled to the substrate and including the first plate.

Abstract: A trackpad includes: a substrate; a circuit board coupled to the substrate for detecting a position of an object adjacent the substrate, the circuit board including a first plate; a second plate including a spring element, wherein a spacer couples the circuit board and the spring element to each other, the spring element facilitating first movement of the substrate and the circuit board relative to the second plate; and a capacitive force sensor that detects a capacitance of the first plate and the second plate. A trackpad can include a spacer coupling the circuit board and the spring element to each other, and facilitating second movement of at least the substrate and the circuit board by a haptic feedback component.

Abstract: A trackpad includes: a substrate; a circuit board coupled to the substrate for detecting a position of an object adjacent the substrate; a haptic feedback component coupled to the circuit board; a first plate coupled to the circuit board; a second plate including a spring element, a spacer coupling the circuit board and the spring element to each other, the spring element facilitating first movement of the substrate, the circuit board and the first plate relative to the second plate, the spacer facilitating second movement of at least the substrate and the circuit board by the haptic feedback component; and a capacitive force sensor that detects a capacitance of the first plate and the second plate. A trackpad can include a circuit board coupled to the substrate and including the first plate.

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Abstract: Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.

Abstract: A system, method and the like for synchronous document captures into an asynchronous archive and document-level reconciliation of the archive process. Once a document requiring archiving has been captured and validated, the client is immediately notified that the document has been accepted into the archiving system and that archiving will ensue. Once the batch mode archiving process has been completed, the client is notified, at the document/individual request-level of the completion of the archive process. Additionally, the archiving system is transparent to the clients in terms of system changes, capable of mitigating system errors and/or notifying clients of system errors, adaptable to allow for any format of web service call requesting document archiving, allows for different types of documents having different index/metadata to be processed without a database schema change and allows users to configure archive process attributes on a per document, or per document-type basis.

Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Abstract: A test and measurement system is disclosed. The system includes a data store with a data description of a received in-phase (I) quadrature (Q) symbol. The received IQ symbol is received from a transmitter associated with impairments, and the received IQ symbol is modified from a corresponding ideal IQ symbol by the impairments. A computer processor is coupled to the data store and generates an Error-Vector Magnitude (EVM) function that describes a difference between the received IQ symbol and the ideal IQ symbol in terms of a plurality of impairment parameters indicating the impairments. The processor then determines values for the impairment parameters that quantify the impairments. The values are determined by selection of values for the impairment parameters that minimize the EVM function.

Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.

Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

Abstract: FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.